Translational Psychiatry

Journal Title：Translational Psychiatry

Psychiatry has suffered tremendously by the limited translational pipeline. Nobel laureate Julius Axelrod's discovery in 1961 of monoamine reuptake by pre-synaptic neurons still forms the basis of contemporary antidepressant treatment. There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients. Translational Psychiatry bridges this gap by fostering and highlighting the pathway from discovery to clinical applications, healthcare and global health. We view translation broadly as the full spectrum of work that marks the pathway from discovery to global health, inclusive. The steps of translation that are within the scope of Translational Psychiatry include (i) fundamental discovery, (ii) bench to bedside, (iii) bedside to clinical applications (clinical trials), (iv) translation to policy and health care guidelines, (v) assessment of health policy and usage, and (vi) global health. All areas of medical research, including — but not restricted to — molecular biology, genetics, pharmacology, imaging and epidemiology are welcome as they contribute to enhance the field of translational psychiatry.

转化渠道有限，给精神病学带来了巨大的损失。诺贝尔奖获得者朱利叶斯·阿克塞尔罗德于 1961 年发现突触前神经元对单胺的再摄取，这仍然是当代抗抑郁治疗的基础。神经科学知识的爆炸式增长与患者概念上新颖的治疗方法之间存在着巨大的差距。转化精神病学通过促进和强调从发现到临床应用、医疗保健和全球健康的途径来弥合这一差距。我们将转化视为从发现到全球健康之路的全方位工作。转化精神病学范围内的转化步骤包括 (i) 基础发现、(ii) 从实验室到临床、(iii) 从临床到临床应用（临床试验）、(iv) 转化为政策和医疗保健指南、(v) 评估卫生政策和使用情况，以及 (vi) 全球健康。欢迎所有医学研究领域，包括但不限于分子生物学、遗传学、药理学、成像和流行病学，因为它们有助于促进转化精神病学领域的发展。

Translational Psychiatry创刊于2011年，由Springer Nature出版商出版，收稿方向涵盖PSYCHIATRY全领域，在行业领域中学术影响力很大，属于TOP期刊，国际一流期刊，关注度和专业度非常高，所以对原创文章要求创新性很高，过审难度很高，如果您有志于TOP期刊，建议关注此刊。平均审稿速度 23 Weeks ，影响因子指数5.8，该期刊近期没有被列入国际期刊预警名单，广大学者值得一试。